Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the Sleeping Beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma

Molecular Therapy

Volumn 12, Issue 5, 2005, Pages 778-788

  Ohlfest, John R ^a   Demorest, Zachary L ^a   Motooka, Yasuhiko ^a   Vengco, Isabelita ^a   Oh, Seunguk ^a   Chen, Eleanor ^b   Scappaticci, Frank A ^c   Saplis, Rachel J ^b   Ekker, Stephen C ^b   Low, Walter C ^a   Freese, Andrew B ^a   Largaespada, David A ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Glioblastoma; Nonviral; Sleeping beauty; Transposon

Indexed keywords

ANGIOSTATIN; ENDOSTATIN; HYBRID PROTEIN; LUCIFERASE; PLASMID DNA; VASCULOTROPIN RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; COMBINATORIAL CHEMISTRY; CONTROLLED STUDY; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; SUBCUTANEOUS TISSUE; THERMODYNAMICS; TRANSGENE; TRANSPOSON; TUMOR REGRESSION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANGIOSTATINS; ANIMALS; BRAIN NEOPLASMS; DNA TRANSPOSABLE ELEMENTS; ENDOSTATINS; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; LUCIFERASES; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PLASMIDS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TRANSPLANTATION, HETEROLOGOUS; TRANSPOSASES;

ANIMALIA;

EID: 27744497800     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2005.07.689     Document Type: Article

References (47)

1. B. Glinski P. Dymek and J. Skolyszewski Altered therapy schedules in postoperative treatment of patients with malignant gliomas: Twenty year experience of the Maria Sklodowska-Curie Memorial Center in Krakow, 1973-1993 J. Neurooncol. 36 1998 159-165
2. S. Takano H. Kamiyama K. Tsuboi and A. Matsumura Angiogenesis and antiangiogenic therapy for malignant gliomas Brain Tumor Pathol. 21 2004 69-73
3. T. Demuth and M.E. Berens Molecular mechanisms of glioma cell migration and invasion J. Neurooncol. 70 2004 217-228
4. P.Y. Lam and X.O. Breakefield Potential of gene therapy for brain tumors Hum. Mol. Genet. 10 2001 777-787
5. D. Hanahan and J. Folkman Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 1996 353-364
6. H.I. Ma et al. Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector Gene Ther. 9 2002 2-11
7. S. De Bouard et al. Antiangiogenic therapy against experimental glioblastoma using genetically engineered cells producing interferon-alpha, angiostatin, or endostatin Hum. Gene Ther. 14 2003 883-895
8. J. Wu X. Zhang and D. Gao [Inhibition of human glioma growth in nude mice by local secretion of angiostatin K(1-3)] Zhonghua Yi Xue Za Zhi 80 2000 861-864
9. J.P. Eder Jr. et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily J. Clin. Oncol. 20 2002 3772-3784
10. F.A. Shepherd and S.S. Sridhar Angiogenesis inhibitors under study for the treatment of lung cancer Lung Cancer 41 Suppl. 1 2003 S63-S72
11. M. Li et al. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy Clin. Cancer Res. 8 2002 3570-3578
12. F.A. Scappaticci et al. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice Mol. Ther. 3 2001 186-196
13. F.A. Scappaticci et al. Statin-AE: A novel angiostatin-endostatin fusion protein with enhanced antiangiogenic and antitumor activity Angiogenesis 4 2001 263-268
14. L. Bello et al. Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma Clin. Cancer Res. 10 2004 4527-4537
15. F. Montemurro G. Valabrega and M. Aglietta Trastuzumab-based combination therapy for breast cancer Expert Opin. Pharmacother. 5 2004 81-96
16. A. Kaubisch R. Kaleya H. Haynes A. Rozenblit and S. Wadler Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors Cancer Chemother. Pharmacol. 53 2004 337-340
17. J.R. Rigas Taxane-platinum combinations in advanced non-small cell lung cancer: A review Oncologist 9 Suppl. 2 2004 16-23
18. J.R. Ohlfest P.D. Lobitz S.G. Perkinson and D.A. Largaespada Integration and long-term expression in xenografted human glioblastoma cells using a plasmid-based transposon system Mol. Ther. 10 2004 260-268
19. Z. Ivics P.B. Hackett R.H. Plasterk and Z. Izsvak Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells Cell 91 1997 501-510
20. Z. Izsvak Z. Ivics and R.H. Plasterk Sleeping Beauty, a wide host-range transposon vector for genetic transformation in vertebrates J. Mol. Biol. 302 2000 93-102
21. J.R. Ohlfest et al. Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system Blood 105 2005 2691-2698
22. S.R. Yant L. Meuse W. Chiu Z. Ivics Z. Izsvak and M.A. Kay Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system Nat. Genet. 25 2000 35-41
23. S.R. Yant A. Ehrhardt J.G. Mikkelsen L. Meuse T. Pham and M.A. Kay Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo Nat. Biotechnol. 20 2002 999-1005
24. E. Montini et al. In vivo correction of murine tyrosinemia type I by DNA-mediated transposition Mol. Ther. 6 2002 759-769
25. I. Yoshimura Y. Mizuguchi A. Miyajima T. Asano T. Tadakuma and M. Hayakawa Suppression of lung metastasis of renal cell carcinoma by the intramuscular gene transfer of a soluble form of vascular endothelial growth factor receptor I J. Urol. 171 2004 2467-2470
26. C.J. Kuo et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer Proc. Natl. Acad. Sci. USA 98 2001 4605-4610
27. H. Niwa K. Yamamura and J. Miyazaki Efficient selection for high-expression transfectants with a novel eukaryotic vector Gene 108 1991 193-199
28. N.A. Kootstra R. Matsumura and I.M. Verma Efficient production of human FVIII in hemophilic mice using lentiviral vectors Mol. Ther. 7 2003 623-631
29. C. Ye et al. sFlt-1 gene therapy of follicular thyroid carcinoma Endocrinology 145 2004 817-822
30. A. De X.Z. Lewis and S.S. Gambhir Noninvasive imaging of lentiviral-mediated reporter gene expression in living mice Mol. Ther. 7 2003 681-691
31. S. Moriuchi et al. Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model Gene Ther. 9 2002 584-591
32. S. Ali et al. Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression Mol. Ther. 10 2004 1071-1084
33. A. Rehemtulla et al. Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging Neoplasia 2 2000 491-495
34. M.S. O'Reilly et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth Cell 88 1997 277-285
35. H.I. Ma et al. Suppression of intracranial human glioma growth after intramuscular administration of an adeno-associated viral vector expressing angiostatin Cancer Res. 62 2002 756-763
36. F. Griscelli et al. Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest Proc. Natl. Acad. Sci. USA 95 1998 6367-6372
37. O. Kisker et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model Cancer Res. 61 2001 7669-7674
38. R. Heidenreich et al. Inhibition of solid tumor growth by gene transfer of VEGF receptor-1 mutants Int. J. Cancer 111 2004 348-357
39. T. Hoshida et al. Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor Pancreas 25 2002 111-121
40. B. Kou et al. In vivo inhibition of tumor angiogenesis by a soluble VEGFR-2 fragment Exp. Mol. Pathol. 76 2004 129-137
41. A. Hajitou et al. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells FASEB J. 16 2002 1802-1804
42. M. Shichiri and Y. Hirata Antiangiogenesis signals by endostatin FASEB J. 15 2001 1044-1053
43. F. Dkhissi et al. Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells Hum. Gene Ther. 14 2003 997-1008
44. K.J. Pulkkanen et al. The combination of HSV-tk and endostatin gene therapy eradicates orthotopic human renal cell carcinomas in nude mice Cancer Gene Ther. 9 2002 908-916
45. A. Immonen et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: A randomised, controlled study Mol. Ther. 10 2004 967-972
46. A.M. Geurts et al. Gene transfer into genomes of human cells by the Sleeping Beauty transposon system Mol. Ther. 8 2003 108-117
47. P.B. Vermeulen et al. Quantification of angiogenesis in solid human tumours: An international consensus on the methodology and criteria of evaluation Eur. J. Cancer 32A 1996 2474-2484